These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 3125342)
1. Effect of acute ethanol administration on brain levels of tetrahydropapaveroline in L-dopa-treated rats. Cashaw JL; Geraghty CA; McLaughlin BR; Davis VE J Neurosci Res; 1987; 18(3):497-503. PubMed ID: 3125342 [TBL] [Abstract][Full Text] [Related]
2. Tetrahydropapaveroline in brain regions of rats after acute ethanol administration. Cashaw JL Alcohol; 1993; 10(2):133-8. PubMed ID: 8442889 [TBL] [Abstract][Full Text] [Related]
3. Cerebroventricular tetrahydropapaveroline infusions and ethanol consumption in the rat. Sinclair JD; Myers RD Subst Alcohol Actions Misuse; 1982; 3(1-2):5-24. PubMed ID: 6890240 [TBL] [Abstract][Full Text] [Related]
4. Precise GC/MS assays for salsolinol and tetrahydropapaveroline: the question of artifacts and dietary sources and the influence of alcohol. Smythe GA; Duncan MW Prog Clin Biol Res; 1985; 183():77-84. PubMed ID: 4048185 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of dopamine biosynthesis by tetrahydropapaveroline. Kim YM; Kim MN; Lee JJ; Lee MK Neurosci Lett; 2005 Sep; 386(1):1-4. PubMed ID: 16026929 [TBL] [Abstract][Full Text] [Related]
6. Increased urinary morphine, codeine and tetrahydropapaveroline in parkinsonian patient undergoing L-3,4-dihydroxyphenylalanine therapy: a possible biosynthetic pathway of morphine from L-3,4-dihydroxyphenylalanine in humans. Matsubara K; Fukushima S; Akane A; Kobayashi S; Shiono H J Pharmacol Exp Ther; 1992 Mar; 260(3):974-8. PubMed ID: 1545408 [TBL] [Abstract][Full Text] [Related]
7. A method for determination of subpicomole concentrations of tetrahydropapaveroline in rat brain by high-performance liquid chromatography with electrochemical detection. Cashaw JL; Geraghty CA; McLaughlin BR; Davis VE Anal Biochem; 1987 Apr; 162(1):274-82. PubMed ID: 3605593 [TBL] [Abstract][Full Text] [Related]
8. Tetrahydropapaveroline and the blood-brain barrier in rats. Cashaw JL; Geraghty CA Alcohol; 1991; 8(4):317-9. PubMed ID: 1872993 [TBL] [Abstract][Full Text] [Related]
9. Effects of tetrahydropapaveroline on dopamine and 5-hydroxytryptamine metabolism in rat brain in vivo. Livrea P; Di Reda L; Giovine A; Bertolino A Pharmacology; 1976; 14(1):20-6. PubMed ID: 134381 [TBL] [Abstract][Full Text] [Related]
10. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552 [TBL] [Abstract][Full Text] [Related]
11. Estimation of the in vivo concentration of salsolinol and tetrahydropapaveroline in rat brain after the administration of ethanol. Weiner H Subst Alcohol Actions Misuse; 1980; 1(3):317-22. PubMed ID: 7347923 [TBL] [Abstract][Full Text] [Related]
12. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats. Rose S; Jenner P; Marsden CD Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899 [TBL] [Abstract][Full Text] [Related]
13. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296 [TBL] [Abstract][Full Text] [Related]
14. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Lindgren HS; Rylander D; Ohlin KE; Lundblad M; Cenci MA Behav Brain Res; 2007 Feb; 177(1):150-9. PubMed ID: 17157933 [TBL] [Abstract][Full Text] [Related]
15. Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by mean of HPLC-EC. Cannazza G; Di Stefano A; Mosciatti B; Braghiroli D; Baraldi M; Pinnen F; Sozio P; Benatti C; Parenti C J Pharm Biomed Anal; 2005 Jan; 36(5):1079-84. PubMed ID: 15620535 [TBL] [Abstract][Full Text] [Related]
16. MAO activity in rat brain stem and cerebral cortex: effect of acute and chronic treatment with ethanol and tetrahydropapaveroline. Renis M; Giovine A; Bertolino A Pharmacology; 1978; 17(1):1-7. PubMed ID: 684069 [TBL] [Abstract][Full Text] [Related]
17. The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment. Mura A; Feldon J; Mintz M Exp Neurol; 2000 Aug; 164(2):322-32. PubMed ID: 10915571 [TBL] [Abstract][Full Text] [Related]
18. Chronic administration does not alter the accumulation of L-dopa into muscle. Rose S; Jenner P; Marsden CD Mov Disord; 1994 Mar; 9(2):167-72. PubMed ID: 8196677 [TBL] [Abstract][Full Text] [Related]
19. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]